Clinical trials: Liver Tumour
Lung Adenocarcinoma, Cancer-related Fatigue
Chaigui Jieyu Qufa Decoction for CRF in Driver Gene-negative Lung Adenocarcinoma Trial
The goal of this [clinical trial] is to [evaluate whether Chaiyu Jieyu Qufa Decoction can improve cancer-related fatigue and assess its safety] in [patients aged 18-80 years with untreated lung adenocarcinoma complicated with…
- Conditions
- Lung Adenocarcinoma, Cancer-related Fatigue, Liver Depression and Spleen Deficiency Syndrome (Traditional Chinese Medicine)
- Trial name
- CJQD-CRF (NCT07890051)
- Testing
- Chai-Gui Jieyu Qufa Granules
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Hepatic Cancer, Hepatic Resection
Immunohistochemical Algorithm for the Diagnosis and Classification of Hepatocellular Carcinomas With TERT, TP53 and CTNNB1 Mutation
The presence of certain mutations in HCC, such as TERT and TP53, have a suspected or proven prognostic role in resected patients, but lack a morphological or immunophenotypic counterpart, which would allow us to define which…
- Trial name
- NCT06718153
- Testing
- Immunohistochemistry and in situ hybridisation analysis
- Where
- Italy
- Volunteers
- 100 people
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
Hepatocellular Carcinoma
SBRT With Atezo/Bev for HCC
A phase I dose escalation and pharmacodynamic study of repeated dose stereotactic body radiotherapy (SBRT) administered with concurrent atezolizumab and bevacizumab for patients with advanced hepatocellular carcinoma (HCC)
- Trial name
- NCT05488522
- Testing
- SBRT + atezolizumab and bevacizumab
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Non Small Cell Lung Cancer, Esophageal Cancer
Tumor Cell and DNA Detection in the Blood, Urine, and Bone Marrow
Patients with resectable solid primary cancers and even limited number of metastases are potentially curable. However, most patients develop recurrences despite surgery.
- Conditions
- Non Small Cell Lung Cancer, Esophageal Cancer, Gastric Cancer, Pancreatic Cancer
- Trial name
- NCT03551951
- Testing
- Test for circulating tumor cells, DNA alterations
- Where
- United States
- Volunteers
- 320 people, healthy volunteers welcome
- Sponsor
- University of Missouri-Columbia
Ann Arbor Stage III B-Cell Non-Hodgkin Lymphoma, Ann Arbor Stage IV B-Cell Non-Hodgkin Lymphoma
Tazemetostat in Treating Patients With Metastatic or Unresectable Solid Tumors or B-Cell Lymphomas With Liver Dysfunction
This phase I trial studies the best dose and side effects of tazemetostat in treating patients with solid tumors or B-cell lymphomas with liver dysfunction that have spread to other places in the body or cannot be removed by…
- Conditions
- Ann Arbor Stage III B-Cell Non-Hodgkin Lymphoma, Ann Arbor Stage IV B-Cell Non-Hodgkin Lymphoma, Metastatic Malignant Solid Neoplasm, Stage III Hepatocellular Carcinoma AJCC v7
- Trial name
- NCT03217253
- Testing
- Laboratory Biomarker Analysis, Pharmacological Study, Tazemetostat
- Where
- United States
- Sponsor
- National Cancer Institute (NCI)
Hepatocellular Carcinoma
to Evaluate the Efficacy and Safety of MG4101(Ex Vivo Expanded Allogeneic NK Cell)
To see the safety and efficacy of injecting MG4101 as a secondary treatment after curative liver resection on the patient with advanced HCC who has high risk of recurrence.
- Trial name
- MG4101 (NCT02008929)
- Testing
- MG4101
- Where
- South Korea
- Volunteers
- 5 people
- Sponsor
- Samsung Medical Center
Colon Cancer
Randomized Phase II Adjuvant Chemotherapy ± FANG™ in Colorectal Carcinoma With Liver Metastases
Preliminary studies with a variety of vaccines suggest target accessibility (potential immunogenicity) in a variety of solid tumors to immune directed approaches.
- Trial name
- FANG-CLM (NCT01505166)
- Testing
- Vigil™ Vaccine
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Gradalis, Inc.
Hepatocellular Carcinoma
Study of the Combination of TACE With Apatinib in Patients With Hepatocellular Carcinoma
Hepatocellular carcinoma (HCC) is the most common primary malignant tumor of the liver. It is lack of effective drugs for systemic treatment of HCC.
- Trial name
- NCT03066557
- Testing
- TACE and Apatinib, TACE
- Volunteers
- 80 people
- Sponsor
- Jiangsu Cancer Institute & Hospital
Inflammatory Hepatocellular Adenoma
A Phase 2 Open-label Single-arm Trial of JAK1 Inhibitor for the Treatment of Large Inflammatory Hepatocellular Adenomas
Hepatocellular adenomas (HCA) are tumors rare benign hepatic infections that develop on a liver normal and in young women taking a estrogen-based contraception.
- Trial name
- JAKIH (NCT06490757)
- Testing
- Baricitinib
- Where
- France
- Volunteers
- 25 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Colorectal Cancer, Liver Metastases
Hepatic Artery Infusion Pump Chemotherapy With Floxuridine and Dexamethasone in Combination With Systemic Chemotherapy for Patients With Colorectal Cancer Metastatic to the Liver
Background: Many people with colorectal cancer get liver metastases. Standard treatment for this is a combination of chemotherapy drugs. Directing the chemotherapy to the liver may be effective.
- Conditions
- Colorectal Cancer, Liver Metastases, Colorectal Adenocarcinoma, Colorectal Cancer With Hepatic Metastases
- Trial name
- NCT03366155
- Testing
- Codman 3000 constant flow pump catheter, Panitumumab, FUDR-Dex
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- National Cancer Institute (NCI)
Hepatocellular Carcinoma
Trial of S-1 in Combination With Sorafenib for Patients With Advanced Hepatocellular Carcinoma
In preclinical studies, 5-fluorouracil, one of the active metabolites of S-1, showed synergistic effect to sorafenib in human colon carcinoma cell lines.
- Trial name
- NCT01131689
- Testing
- sorafenib, TS-1
- Where
- South Korea
- Volunteers
- 20 people
- Sponsor
- Samsung Medical Center
Hepatocellular Carcinoma, Adult
PIN in Combination With Anti-PD1 in Previously Treated Primary Hepatocellular Carcinoma
In this single-center,open-label, phase I study, the safety and efficacy of PIN in combination with programmed cell death protein antibody (anti-PD1) therapeutic regimen will be evaluated in patients with refractory primary…
- Trial name
- NCT07018518
- Testing
- PIN +anti-PD1
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Chinese PLA General Hospital
End Stage Liver Disease, Acute Liver Failure
Robotic vs. Laparoscopic vs. Open Living Donor Hepatectomy
This will be a study to examine the outcomes of open, laparoscopic, and robotic Living Donor Liver Transplantation (LDLT) procedures.
- Conditions
- End Stage Liver Disease, Acute Liver Failure, Acute-On-Chronic Liver Failure, Hepatocellular Carcinoma
- Trial name
- NCT06062706
- Testing
- Donor hepatectomy
- Where
- Saudi Arabia
- Volunteers
- 3,448 people
- Sponsor
- King Faisal Specialist Hospital & Research Center
Radiomics, Hepatocellular Carcinoma (HCC)
Microvascular Invasion for Guiding Treatment of Barcelona Clinic Liver Cancer Stage B Hepatocellular Carcinoma
The goal of this observational study is to explore the role of prediction of microvascular invasion by radiomics based on pre-treatment magnetic resonance imaging for guiding treatment of Barcelona Clinic Liver Cancer stage B…
- Conditions
- Radiomics, Hepatocellular Carcinoma (HCC), Transcatheter Arterial Chemoembolization (TACE), Microvascular Invasion (MVI)
- Trial name
- NCT05889949
- Testing
- Sorafenib, Lenvatinib
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Sun Yat-sen University
Liver Cancer, Metastatic Cancer
Radiolabeled Glass Beads in Treating Patients With Metastatic Liver Cancer That Cannot Be Removed by Surgery
RATIONALE: Internal radiation therapy uses radioactive material placed directly into or near a tumor to kill tumor cells. Using radiolabeled glass beads to kill tumor cells may be effective treatment for liver cancer that cannot…
- Trial name
- NCT00532740
- Testing
- Yttrium Y 90 glass microspheres
- Where
- United States
- Volunteers
- 2,000 people
- Sponsor
- Northwestern University
Hepatocellular Carcinoma, Portal Vein Tumor Thrombus
Stereotactic Ablative Radiotherapy for Hepatocellular Carcinoma With Major Portal Vein Invasion
Recently, several studies reported promising outcomes of patients after external beam radiotherapy (EBRT) for hepatocellular carcinoma (HCC) with portal vein tumor thrombosis.
- Trial name
- NCT01850368
- Testing
- Stereotactic ablative radiotherapy
- Where
- 8 sites in South Korea
- Volunteers
- 35 people
- Sponsor
- Korea Cancer Center Hospital
Hepatocellular Carcinoma
Computer-assisted Tumor Ablation for Patients With Liver Cancer
In patients with primary liver cancer arising from the liver cells, several treatment options are available according to the stage of the disease.
- Trial name
- NCT03630068
- Testing
- Stereotactic percutaneous image-guided microwave ablation
- Where
- Switzerland
- Volunteers
- 87 people
- Sponsor
- Insel Gruppe AG, University Hospital Bern
Advanced Hepatocellular Carcinoma
Camrelizumab Utilization on Patients With Advanced Liver Cancer
To observe and evaluate the safety and efficacy of camrelizumab in advanced liver cancer
- Trial name
- NCT04487704
- Testing
- camrelizumab
- Where
- China
- Volunteers
- 1,000 people
- Sponsor
- First Affiliated Hospital Xi'an Jiaotong University
Liver Surgery, Hepatectomy
ACS-NSQIP Calculator for Liver Surgery
The American College of Surgeons National Surgical Quality Improvement Program's (ACS-NSQIP) calculator has been endorsed by the surgeons' community to counsel patients and relatives regarding estimated postoperative…
- Conditions
- Liver Surgery, Hepatectomy, Outcome After Hepatectomy
- Trial name
- NCT03793933
- Testing
- Liver resection
- Volunteers
- 450 people
- Sponsor
- Humanitas Clinical and Research Center
Liver Transplant; Complications
Influence of Intraoperative Blood Salvage and Autotransfusion on Tumor Recurrence After Deceased Donor Liver Transplantation
The practice of intraoperative blood salvage and autotransfusion (IBSA) during deceased donor liver transplantation (DDLT) for hepatocellular carcinoma (HCC) can potentially reduce the need for allogeneic blood transfusion.
- Trial name
- NCT06307158
- Volunteers
- 998 people
- Sponsor
- Zhejiang University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.